A FormBlends network publication
FormBlends Video Library

Playlist player

Pick one of the six playlists and watch it in order. Each entry is a click-to-load YouTube embed beside the fact-check summary: what the video gets right, what it leaves out or overstates, and a link to the full write-up with its FDA label and PubMed sources. Runs entirely in your browser.

By FormBlends editorial teamAssumptions checked September 4, 2026Runs in your browser; nothing is sent to a server

How GLP-1s work: 5 videos, about 67 minutes in total. Watch in order; each write-up assumes the ones before it.

Playlist page

  1. 1 of 5 · 1:27

    What is a GLP-1 agonist, and how does it work? | Ohio State Medical Center

    Ohio State Wexner Medical Center · Original

    Gets right: A 90-second hospital explainer that gets the essentials right: GLP-1 agonists mimic a gut hormone, act on receptors in the brain and gastrointestinal tract, affect appetite and satiety as well as glucose, and semaglutide's cardiovascular benefit appears partly independent of weight loss.

    Leaves out: No numbers, no side effects, no label warnings, and the claim that people with obesity make less GLP-1 is more contested in the literature than the video implies.

    Read the full fact-check

  2. 2 of 5 · 6:32

    Role of GLP-1 Receptor Agonists for Weight Loss

    Harvard Medical School Continuing Education · Original

    Gets right: A Brigham and Women's endocrinologist walks through the trials that established liraglutide and semaglutide for weight management: SCALE, STEP 1, STEP 8 and STEP 4, with the correct primary numbers for each.

    Leaves out: Recorded in 2022, so it predates tirzepatide's approval, the SELECT cardiovascular results and the higher-dose semaglutide data; it also does not quantify adverse events or dropouts.

    Read the full fact-check

  3. 3 of 5 · 17:16

    Pharmacology - DRUGS FOR DIABETES (MADE EASY)

    Speed Pharmacology · Original

    Gets right: A pharmacology educator's overview of every diabetes drug class, with a compact and accurate account of the incretin effect, DPP-4 degradation, and why GLP-1 mimetics slow gastric emptying, promote satiety and cause weight loss.

    Leaves out: From 2017, so semaglutide, tirzepatide and the obesity indications are absent; the pancreatitis discussion reflects the signal as it stood then and the incretin segment is a few minutes of a longer diabetes lecture.

    Read the full fact-check

  4. 4 of 5 · 38:02

    Ep 3: Inside GLP-1s: How They Work, Who They Help & What to Expect | Medicine Made General

    Johns Hopkins Medicine · Original

    Gets right: A 38-minute Johns Hopkins podcast with an obesity medicine physician: body composition and ageing, why lifestyle alone rarely holds more than 5 to 8 percent, GLP-1s as long-term therapy like a statin, what the first weeks feel like, and a candid answer on compounded products.

    Leaves out: Conversational and unreferenced, so the trial numbers are approximate; the compounding section describes the law as of mid-2025 and should be read with the FDA's current position.

    Read the full fact-check

  5. 5 of 5 · 3:15

    GLP-1 weight-loss drugs: What the science says | 90 Seconds w/ Lisa Kim

    Stanford Medicine · Original

    Gets right: A three-minute Stanford Medicine piece with several faculty: the class has been prescribed since 2005, the benefits reach the heart, kidneys, liver and sleep apnoea, the common side effects are gastrointestinal, and weight bias shapes how side effects are judged.

    Leaves out: The 30 to 50 percent cardiovascular risk reduction quoted is broader than the SELECT result of 20 percent; the muscle-loss reassurance is clinical opinion rather than trial data.

    Read the full fact-check

Assumptions, checked September 4, 2026

  • Playlists are editorial groupings by the FormBlends editorial team, not YouTube playlists, and not curated or endorsed by the channels.
  • Each embed uses YouTube's privacy-enhanced player and loads only when clicked. Thumbnails come from i.ytimg.com; FormBlends hosts no video or image files.
  • Every video id was confirmed against YouTube's public oEmbed endpoint on the date shown; if a video is removed by its channel the page is retired rather than replaced with a copy.
  • Summaries are our reading of each video against the FDA label and the primary trial publication cited on the video's page. They are educational, not medical advice.

This calculator is an arithmetic aid for medication a licensed prescriber has already prescribed. It does not recommend a dose. Confirm any result with your prescriber or pharmacist before use.

Sources

  1. How we choose videos (methodology)
  2. YouTube: Embed videos and playlists
  3. DailyMed (FDA labels cited in the fact-checks)
  4. PubMed (trial publications cited in the fact-checks)

Read before you use it

Guides for this calculator

Playlist: How GLP-1s work

Five videos on mechanism, from a 90-second hospital explainer to a 38-minute academic podcast, in the order that builds understanding. Each has a written fact-check with the label and trial sources.

Updated September 4, 2026

Playlist: Tirzepatide

Four videos on the dual GIP and GLP-1 agonist: a journal summary of an off-label study, a specialist journal club, a conversation with a SURPASS investigator, and a head-to-head with semaglutide from a diabetes nonprofit.

Updated September 4, 2026

Playlist: Semaglutide

Four videos on semaglutide: NEJM and Cleveland Clinic on the SELECT cardiovascular trial, a Harvard teaching video on prescribing, and a 45-minute clinic question and answer.

Updated September 4, 2026

Educational, not medical advice. Read the medical disclaimer.